Cargando…

COVID-19-Impfung unter Psychopharmakotherapie

Vaccines against SARS-CoV-2 have been available in the European Union since December 2020. Persons suffering from mental illness have an increased risk of a severe or fatal course following an infection with SARS-CoV-2. Thus, the question arises to what extent interactions between the newly approved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seifert, Johanna, Heck, Johannes, Eckermann, Gabriel, Singer, Monika, Bleich, Stefan, Grohmann, Renate, Toto, Sermin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570910/ https://www.ncbi.nlm.nih.gov/pubmed/34344044 http://dx.doi.org/10.1055/a-1531-4460

Ejemplares similares

Psychopharmakotherapie in Zeiten der COVID-19-Pandemie
por: Seifert, J., et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics
por: Moschny, Nicole, et al.
Publicado: (2021)

Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries
por: Reinhard, Matthias A., et al.
Publicado: (2020)

Spermienqualität leidet nicht unter Corona-Impfung
por: Grütz, Moritz
Publicado: (2021)

Psychopharmakotherapie in der Pandemie: Interaktionen beachten
por: Klein, Friederike
Publicado: (2021)

Psychotropic drug-induced hyponatremia: results from a drug surveillance program–an update
por: Seifert, Johanna, et al.
Publicado: (2021)

A case series of serious and unexpected adverse drug reactions under treatment with cariprazine
por: Heck, Johannes, et al.
Publicado: (2021)

Peripandemic psychiatric emergencies: impact of the COVID-19 pandemic on patients according to diagnostic subgroup
por: Seifert, Johanna, et al.
Publicado: (2021)

Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017
por: Seifert, Johanna, et al.
Publicado: (2021)

Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001–2017
por: Seifert, Johanna, et al.
Publicado: (2022)

Clinical and sociodemographic predictors of inpatient admission after presentation in a psychiatric emergency room: an observational study
por: Gisy, Gianna L., et al.
Publicado: (2023)

Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data
por: de Bardeci, Mateo, et al.
Publicado: (2022)

SARS-CoV-2-Antikörper-Antwort auf die zweite COVID-19-Impfung bei neuromuskulären Patienten unter immunmodulierender Therapie
por: Hosseini, S. S. Justus, et al.
Publicado: (2022)

Update COVID-19-Impfung
por: Wagner, Laura, et al.
Publicado: (2023)

Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010
por: Spindelegger, Christoph Josef, et al.
Publicado: (2015)

Clozapin aus Sicht des Projekts "Arzneimittelsicherheit in der Psychiatrie"
por: Dabbert, Dominik, et al.
Publicado: (2022)

Hautreaktionen nach COVID-19-Impfung
por: Müller, Thomas
Publicado: (2021)

Kopfschmerzen nach COVID-19-Impfung
por: Schumacher, Beate
Publicado: (2022)

Bereitschaft zur COVID-19-Impfung unter Beschäftigten im Gesundheitswesen in Deutschland: Befragungsergebnisse aus dem Netzwerk Universitätsmedizin (NUM), November 2020 bis Januar 2021
por: Schug, Caterina, et al.
Publicado: (2021)

Management des Anaphylaxie-Risikos bei Covid-19-Impfung
por: Worm, Margitta, et al.
Publicado: (2021)

Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015
por: Glocker, C., et al.
Publicado: (2021)

Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project
por: Stübner, Susanne, et al.
Publicado: (2018)

COVID-19-Impfung: Vorgehen bei Allergien
por: Bäurle, Anne
Publicado: (2021)

Allergie-Patienten und COVID-19-Impfung
Publicado: (2021)

Neurologische Nebenwirkungen der COVID-19-Impfung
por: Diener, Hans-Christoph, et al.
Publicado: (2022)

Breitere Wirkung der COVID-19-Impfung?
por: Geissel, Wolfgang
Publicado: (2022)

COVID-19-Impfung bei immunsupprimierten Rheumatikern
por: Facharztmagazine, Redaktion
Publicado: (2022)

Cluster-Kopfschmerz nach COVID-19-Impfung?
por: Gaul, Charly
Publicado: (2022)

Cluster-Kopfschmerz nach COVID-19-Impfung?
por: Gaul, Charly
Publicado: (2022)

Q & A zur COVID-19-Impfung
Publicado: (2023)

Einstellung zur Impfung gegen SARS-CoV-2: Umfrage unter Mitarbeitenden in Krankenhäusern vor und nach Beginn der Impfungen in den deutschen Krankenhäusern
por: Janssens, Uwe, et al.
Publicado: (2021)

Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016
por: Glocker, Catherine, et al.
Publicado: (2023)

Aripiprazole treatment for temper outbursts in Prader–Willi syndrome
por: Deest, Maximilian, et al.
Publicado: (2022)

Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study
por: Toto, Sermin, et al.
Publicado: (2019)

Hämoptoe unter Immunsuppression
por: Sander, Thomas, et al.
Publicado: (2022)

COVID-19-Impfung auch bei Allergien sicher
Publicado: (2021)

Extrem selten: COVID-19-Tod trotz Impfung
por: Zink, Nicola
Publicado: (2021)

Myokarditis nach COVID-19-mRNA-Impfung
por: Kerbl, Reinhold
Publicado: (2021)

Kein erhöhtes Abortrisiko nach COVID-19-Impfung
por: Müller, Thomas
Publicado: (2021)

Risiko eines Herzinfarkts nach COVID-19-Impfung
por: Schlimpert, Veronika
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d6b0jj8ic7k30c9icl6ni2j5nr